Personalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms - Top-Institutions - MDSpire

Personalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms

  • By

  • Christoph J Auernhammer

  • Katharina Wang

  • Umberto Maccio

  • Thomas Knösel

  • Maximilian P Hungbauer

  • Katharina Schilbach

  • Julian Maurer

  • Lea Peischer

  • Astrid Reul

  • Elena Kuzmenko

  • Edlira Luca

  • Julia Hamati

  • Diana Vetter

  • Jose Oberholzer

  • Ralph Fritsch

  • Karel Pacak

  • Ashley B Grossman

  • Felix Beuschlein

  • Martin Reincke

  • Constanze Hantel

  • Kathrin Zitzmann

  • Svenja Nölting

  • January 10, 2026

  • 0 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Neuroendocrine Tumors
    • Precision Oncology
    • Translational Cancer Research

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Neuroendocrine Tumors
    • Precision Medicine
    • Cancer Pharmacology

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Neuroendocrine Tumors
    • Personalized Oncology
    • Clinical Pharmacology

  • #4

    National Cancer Institute (NCI)
    National Cancer Institute (NCI)

    Bethesda, MD

    Key Differentiators

    • Cancer Biology
    • Neuroendocrine Tumors
    • Precision Oncology

  • #5

    University of Texas MD Anderson Cancer Center
    University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Neuroendocrine Tumors
    • Translational Oncology
    • Precision Medicine

Original Source(s)

Personalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms

  • by Christoph J Auernhammer, Katharina Wang, Umberto Maccio, Thomas Knösel, Maximilian P Hungbauer, Katharina Schilbach, Julian Maurer, Lea Peischer, Astrid Reul, Elena Kuzmenko, Edlira Luca, Julia Hamati, Diana Vetter, Jose Oberholzer, Ralph Fritsch, Karel Pacak, Ashley B Grossman, Felix Beuschlein, Martin Reincke, Constanze Hantel, Kathrin Zitzmann, Svenja Nölting

  • January 10, 2026

Related Content

Associations of Overweight and Obesity Indicators with Cardiometabolic Risk Profile in Children and Adolescents with Congenital Heart Disease

Predictors of early response to GnRH and gonadotropin therapy in pediatric patients with suspected dual congenital hypogonadotropic hypogonadism: a retrospective single-center study

Correction: Regulatory actions of LH and follicle-stimulating hormone on breast cancer cells and mammary tumors in rats